In the current context of the pandemic triggered by SARS-COV-2, the immunization of the population through vaccination is recognized as a public health priority. In the case of SARS‑COV‑2, the genetic sequencing was done quickly, in one month. Since then, worldwide research has focused on obtaining a vaccine. This has a major economic impact because new technological platforms and advanced genetic engineering procedures are required to obtain a COVID‑19 vaccine. The most difficult scientific challenge for this future vaccine obtained in the laboratory is the proof of clinical safety and efficacy. The biggest challenge of manufacturing is the construction and validation of production platforms capable of making the vaccine on a large scale.

Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review) / Calina, D.; Docea, A. O.; Petrakis, D.; Egorov, A. M.; Ishmukhametov, A. A.; Gabibov, A. G.; Shtilman, M. I.; Kostoff, R.; Carvalho, F.; Vinceti, M.; Spandidos, D. A.; Tsatsakis, A.. - In: INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE. - ISSN 1791-244X. - 46:1(2020), pp. 3-16. [10.3892/ijmm.2020.4596]

Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review)

Vinceti M.;
2020

Abstract

In the current context of the pandemic triggered by SARS-COV-2, the immunization of the population through vaccination is recognized as a public health priority. In the case of SARS‑COV‑2, the genetic sequencing was done quickly, in one month. Since then, worldwide research has focused on obtaining a vaccine. This has a major economic impact because new technological platforms and advanced genetic engineering procedures are required to obtain a COVID‑19 vaccine. The most difficult scientific challenge for this future vaccine obtained in the laboratory is the proof of clinical safety and efficacy. The biggest challenge of manufacturing is the construction and validation of production platforms capable of making the vaccine on a large scale.
2020
6-mag-2020
46
1
3
16
Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review) / Calina, D.; Docea, A. O.; Petrakis, D.; Egorov, A. M.; Ishmukhametov, A. A.; Gabibov, A. G.; Shtilman, M. I.; Kostoff, R.; Carvalho, F.; Vinceti, M.; Spandidos, D. A.; Tsatsakis, A.. - In: INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE. - ISSN 1791-244X. - 46:1(2020), pp. 3-16. [10.3892/ijmm.2020.4596]
Calina, D.; Docea, A. O.; Petrakis, D.; Egorov, A. M.; Ishmukhametov, A. A.; Gabibov, A. G.; Shtilman, M. I.; Kostoff, R.; Carvalho, F.; Vinceti, M.; ...espandi
File in questo prodotto:
File Dimensione Formato  
ijmm_46_1_3_PDF (1).pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 637.72 kB
Formato Adobe PDF
637.72 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1208570
Citazioni
  • ???jsp.display-item.citation.pmc??? 186
  • Scopus 210
  • ???jsp.display-item.citation.isi??? 213
social impact